UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net income (loss) including noncontrolling interests in subsidiaries	$ 9,447	$ (73,266)
Adjustments to reconcile net income (loss) including noncontrolling interests in subsidiaries to net cash used in operating activities:
Depreciation and amortization	3,381	3,369
Amortization of debt discount and issuance costs	0	51
Change in fair value of Series A redeemable convertible preferred stock embedded derivatives	(5,023)	(3,942)
Change in fair value of Series A warrants	0	(896)
Change in fair value of Series B warrants	(11,628)	(23,260)
Compensation expense for share-based awards	477	1,174
(Gain) loss on foreign currency exchange	(80)	813
Change in fair value of equity securities	(3,343)	172,203
Gain (loss) on sale of equity securities	1,361	(66,876)
Deferred income taxes	(240)	(15,039)
Changes in assets and liabilities:
Accounts receivable	(451)	318
Inventories	(503)	(1,084)
Prepaid expenses and other assets	(391)	(1,246)
Accounts payable and accrued expenses	2,355	4,261
Royalties and contingent legal fees payable	360	(161)
Deferred revenue	(71)	418
Net cash used in operating activities	(4,349)	(3,163)
Cash flows from investing activities:
Purchases of equity securities	(5,166)	(92,877)
Sales of equity securities	8,032	102,842
Purchases of property and equipment	(83)	(34)
Net cash provided by investing activities	2,783	9,931
Cash flows from financing activities:
Repurchase of common stock	0	(10,988)
Paydown of Senior Secured Notes	0	(15,000)
Dividend on Series A Redeemable Convertible Preferred Stock	(700)	(700)
Taxes paid related to net share settlement of share-based awards	(416)	(72)
Proceeds from Rights Offering	79,111	0
Net cash provided by (used in) financing activities	77,995	(26,760)
Effect of exchange rates on cash and cash equivalents	12	0
Increase (decrease) in cash and cash equivalents	76,441	(19,992)
Cash and cash equivalents, beginning	287,786	309,361
Cash and cash equivalents, ending	364,227	289,369
Supplemental schedule of cash flow information:
Income taxes paid	147	2
Noncash investing and financing activities:
Accrued patent costs	$ 6,000	$ 0